Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility and Acceptability of AVATAR Therapy in Eating Disorders.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04778423
Recruitment Status : Completed
First Posted : March 3, 2021
Last Update Posted : March 2, 2022
Sponsor:
Information provided by (Responsible Party):
King's College London

Brief Summary:
This project will answer the overarching research question "What is the feasibility of developing and implementing AVATAR therapy to reduce the power of the eating disorder voice in patients with eating disorders?". AVATAR therapy for eating disorders has been developed based on AVATAR therapy for psychosis. The feasibility of using AVATAR therapy in eating disorders will be tested using non-concurrent multiple baselines single case experimental design. The first stage (A1) will involve participants being randomly allocated to either a two, three or four week-baseline. The second will be the intervention phase (B) where participants will receive the AVATAR treatment which will last approximately 6 weeks. The third stage (A2) will be a 4-week follow-up period after the intervention phase, where participants will also complete a qualitative interview.

Condition or disease Intervention/treatment Phase
Eating Disorders Other: Avatar Therapy Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: AVATAR Therapy to Reduce the Power of the Eating Disorder Voice in Eating Disorders: Collaborative Development and Feasibility Testing
Actual Study Start Date : August 5, 2021
Actual Primary Completion Date : January 31, 2022
Actual Study Completion Date : January 31, 2022

Arm Intervention/treatment
Experimental: Avatar Therapy
AVATAR therapy for eating disorders
Other: Avatar Therapy
In the first session (assessment), participants will create a computerised representation of the eating disorder voice (avatar) on a computer. They will be able to manipulate the facial and voice characteristics of the avatar and will be asked to provide examples of the critical eating disorder comments most often spoken by the avatar. In the following sessions (6-8 therapy sessions), participants will interact with the avatar displayed on the computer screen for 5-10 minutes.The main goal during the interaction with the avatar is for participants to stand up to the critical comments made by the avatar and build a sense of power, control and self-awareness in the context of the eating disorder voice. The sessions will be conducted remotely, using a personal laptop or computer. This will provide patients with the opportunity to practise answering back to the eating disorder voice during a meal, a time at which the eating disorder voice is loudest.




Primary Outcome Measures :
  1. Feasibility of AVATAR therapy for eating disorder [ Time Frame: 18 months ]
    Recruitment of 80% or more of the targeted sample size in 18 months and 80% retention to the study protocol at 6-8 weeks (end of therapy).


Secondary Outcome Measures :
  1. Adherence [ Time Frame: 18 months ]
    Adherence to AVATAR therapy: 80% of patients completing at least 5 sessions (based on average attendance of 5 sessions in the psychosis's trial)

  2. Acceptability [ Time Frame: 18 months ]
    Participants' satisfaction with the AVATAR therapy (80% of participants reporting a satisfaction rating over 7, on a Likert scale ranging from 0 "not satisfied at all" to 10 "very satisfied"

  3. Eating disorder voice characteristics [ Time Frame: 12 to 15 weeks depending on the baseline allocation ]
    Estimation of effect size and standard deviation of change in power of the eating disorder voice which will be measured by the auditory hallucination subscale of the psychotic symptom rating scale adapted for eating disorders, the beliefs about the voices questionnaires adapted for eating disorders and a brief weekly survey to assess the content and perceived power of the eating disorder voice.

  4. Eating disorder symptoms [ Time Frame: 12 to 15 weeks depending on the baseline allocation ]
    Eating disorder symptoms will be measured by the Eating disorder examination questionnaire (EDE-Q)

  5. Anxiety and depression [ Time Frame: 12 to 15 weeks depending on the baseline allocation ]
    Measured by the Depression, Anxiety and stress scales (DASS-21)

  6. Self-criticism and self-compassion [ Time Frame: 12 to 15 weeks depending on the baseline allocation ]
    Measured by self-criticism and self-compassion scale



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • diagnosis of anorexia nervosa or atypical anorexia nervosa (e.g. restored weight but presence of abnormal eating disorder cognitions and behaviors), bulimia nervosa or binge eating disorder
  • availability of a laptop and internet connection for the assessments and sessions

Exclusion Criteria:

  • diagnosis of psychosis, alcohol use disorder, substance use disorder
  • insufficient level of English to engage in the therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04778423


Locations
Layout table for location information
United Kingdom
King's College London
London, United Kingdom
Sponsors and Collaborators
King's College London
Publications:
Layout table for additonal information
Responsible Party: King's College London
ClinicalTrials.gov Identifier: NCT04778423    
Other Study ID Numbers: 292346
First Posted: March 3, 2021    Key Record Dates
Last Update Posted: March 2, 2022
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Feeding and Eating Disorders
Pathologic Processes
Mental Disorders